Intellia Therapeutics, Inc. Aktie News

CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on February 1, 2026, it awarded inducement grants to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.

Intellia Therapeutics is reinstated as a Buy, driven by two late-stage in-vivo gene therapy programs: lonvo-z and nex-z. Key 2026 catalysts are the MAGNITUDE clinical hold decision for ATTR-CM and Phase 3 lonvo-z HAE data readout, both with significant valuation impact. Lonvo-z offers potential for a one-time, functional cure in HAE, with strong efficacy and a manageable safety profile, but mar...

Intellia Therapeutics stock surged Tuesday after the FDA aid it would allow the company to restart a gene-editing study.

Intellia Therapeutics said on Tuesday that the U.S. Food and Drug Administration has lifted a clinical hold on one of its gene therapy late-stage trial, allowing the company to resume testing its experimental drug for a rare nerve disease.

Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

The president and CEO of Intellia Therapeutics sold 34,146 directly held shares of the firm on Jan. 5. The sale represented 3.09% of John M.

CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 9:00 a.m. PT.

A clinical hold and a complex commercial path make Intellia Therapeutics' outlook uncertain. Despite steadily growing revenue, Iovance Biotherapeutics faces nearly insurmountable challenges.